Clinical trials / NCT06790966
NCT06790966Phase 3Terminated

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Study sponsor: PDS Biotechnology Corp. · PDSB

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2026-08-25Actual
Enrollment · participants12Actual
Source updated2026-09-02Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

252 participants (planned)

+ After

12 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Feb 2029

+ After

25 Aug 2026

Recruitment status changed

− Before

Active not recruiting

+ After

Terminated

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Overall Survival (OS)

+ After

Measure: Overall Survival (OS) Measure: Progression-Free Survival (PFS)

Planned enrollment decreased by 99 participants

− Before

351 participants (planned)

+ After

252 participants (planned)

Check registry source

· 1 field changed

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source